Leman Biotech is a clinical-stage biotech company. We are a spin-off of EPFL, dedicated to develop next-generation metabolic cancer immunotherapies. Our exclusive metabolic reprogramming technology reverses T-cell exhaustion, a major bottleneck in cancer immunotherapies.
Products, services, technology
We have two products under development: the Meta10-19 CAR-T cell therapy, in clinical stage, has shown great promise in low-dose treatment for recurrent or refractory lymphoma; the IL-10/Fc protein drug, in CMC stage, has demonstrated impressive results up to 90% cure rate in preclinical studies.
Cooperation possibilities
R&D, co-development, partnering, licensing, funding.
Some insights
We make a difference by developing innovative cutting-edge cancer immunotherapies with the potential to cure solid tumors and strive to improve the quality of life for patients and their families.
We are the only known metabolic immunotherapy company to integrate the most advanced technologies like artificial intelligence, genome editing, metabolic immunoengineering to overcome T cell exhaustion - a major bottleneck of T-cell immunotherapy.
Networking opportunities
Investors, scientific collaborators, pharmaceutical companies interested in partnering